Cargando…

Metronomic chemotherapy for triple negative breast cancer?

Detalles Bibliográficos
Autores principales:	Di Desidero, Teresa, Kerbel, Robert S., Bocci, Guido
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925814/ https://www.ncbi.nlm.nih.gov/pubmed/27084985 http://dx.doi.org/10.18632/aging.100947

Ejemplares similares

Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer
por: Di Desidero, Teresa, et al.
Publicado: (2015)

Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth
por: Parra, Karla, et al.
Publicado: (2017)

Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?
por: Cazzaniga, M. E., et al.
Publicado: (2017)

Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key
por: Rabanal, Connie, et al.
Publicado: (2017)

Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers
por: Allegrini, Giacomo, et al.
Publicado: (2012)

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib
por: Bocci, G, et al.
Publicado: (2008)

Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion
por: Muñoz, Raquel, et al.
Publicado: (2019)

Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study
por: Cazzaniga, M. E., et al.
Publicado: (2021)

Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers
por: Schito, Luana, et al.
Publicado: (2020)

Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24–25 June 2014, Milan
por: Bouche, Gauthier, et al.
Publicado: (2014)

Metronomic chemotherapy
por: Maiti, Rituparna
Publicado: (2014)

Metronomic Chemotherapy
por: Cazzaniga, Marina Elena, et al.
Publicado: (2021)

Metronomic Chemotherapy in Pediatric Oncology: From Preclinical Evidence to Clinical Studies
por: Banchi, Marta, et al.
Publicado: (2022)

Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma?
por: Kim, Do Young
Publicado: (2017)

Metronomic Chemotherapy in Prostate Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2022)

Triple-Negative Breast Cancer
por: Chu, Quyen D., et al.
Publicado: (2012)

Low‐dose metronomic chemotherapy improves tumor control in nasopharyngeal carcinoma
por: Chen, Yu‐Pei, et al.
Publicado: (2022)

A Pilot Study of Extended Adjuvant Therapy with Metronomic Docetaxel for Patients with Operable Triple-Negative Breast Cancer
por: Abdelmaksoud, Bader A, et al.
Publicado: (2020)

A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients
por: Allegrini, G, et al.
Publicado: (2008)

Losartan improves the therapeutic effect of metronomic cyclophosphamide in triple negative mammary cancer models
por: Mainetti, Leandro E., et al.
Publicado: (2020)

Head and neck cancer: metronomic chemotherapy
por: De Felice, Francesca, et al.
Publicado: (2015)

Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells
por: Di Desidero, Teresa, et al.
Publicado: (2019)

Stratifying the stratifiers of triple negative breast cancer
por: Wang, Dong-Yu, et al.
Publicado: (2020)

Role of Muscarinic Acetylcholine Receptors in Breast Cancer: Design of Metronomic Chemotherapy
por: Sales, María E., et al.
Publicado: (2019)

Current Research Status of Metronomic Chemotherapy in Combination Treatment of Breast Cancer
por: Liu, Jiaxuan, et al.
Publicado: (2022)

Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer
por: Khan, Kabir A., et al.
Publicado: (2020)

The metronomic combination of paclitaxel with cholinergic agonists inhibits triple negative breast tumor progression. Participation of M(2) receptor subtype
por: Español, Alejandro J., et al.
Publicado: (2020)

Next generation metronomic chemotherapy—report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6–8 May 2016, Mumbai
por: Pantziarka, Pan, et al.
Publicado: (2016)

VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide
por: Orlandi, P, et al.
Publicado: (2013)

Triple negative breast cancer: A continuing challenge
por: Gupta, Sudeep
Publicado: (2013)

Targeting MYC for triple-negative breast cancer treatment
por: Klauber-DeMore, Nancy, et al.
Publicado: (2018)

Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
por: Molto Valiente, Consolacion, et al.
Publicado: (2023)

Sacituzumab govitecan in triple-negative breast cancer
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

Stratifying triple-negative breast cancer: which definition(s) to use?
por: Adamo, Barbara, et al.
Publicado: (2011)

Neoadjuvant immunotherapy in early-stage triple negative breast cancer
por: Laouris, Panayiotis, et al.
Publicado: (2023)

Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
por: Pujade-Lauraine, Eric
Publicado: (2013)

The efficacy and toxicity profile of metronomic chemotherapy for metastatic breast cancer: A meta-analysis
por: Liu, Yangyang, et al.
Publicado: (2017)

Whether low-dose metronomic oral cyclophosphamide improves the response to docetaxel in first-line treatment of non-triple-negative metastatic breast cancer
por: Zhang, Jian, et al.
Publicado: (2017)

Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models
por: Hackl, Christina, et al.
Publicado: (2013)

Metronomic palliative chemotherapy in maxillary sinus tumor
por: Patil, Vijay M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ntrkr9s99esoo4jd009vr42hel